The limited role of comprehensive staging work‐up in ocular adnexal extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue type (MALToma) with excellent prognosis.

4 ‡ Parotid gland (from stage IE to IVE), stomach (from stage IE to IVE, confirmed on EGD), thigh muscle (from stage IE to IVE), iliac/inguinal lymph nodes (stage IIE to IVE). 5 § The bone marrow involvement of mucosa-associated lymphoid tissue (MALT) lymphoma was not detectable by PET or CT scans. Keywords: ocular adnexal lymphoma; extranodal marginal zone lymphoma; MALToma; positron emission tomography; bone marrow biopsy; esophagogastroduodenoscopy EN ocular adnexal lymphoma extranodal marginal zone lymphoma MALToma positron emission tomography bone marrow biopsy esophagogastroduodenoscopy 848 851 4 05/17/21 20210515 NES 210515 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) accounts for 30-90% of ocular adnexal lymphoma, and a majority of ocular adnexal MALT lymphoma (OAML) is stage 1 disease.1 The role of extensive staging procedures, including positron emission tomography-computed tomography (PET-CT), esophagogastroduodenoscopy (EGD), and bone marrow biopsy, has not been thoroughly investigated for OAML due to its rarity. Half of stage IIE patients ( I n i = 4/8) and two-thirds of stage IV patients ( I n i = 6/9) received rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). [Extracted from the article]